Eli Lilly (LLY) becomes the world’s first trillion-dollar healthcare company, driven by demand for obesity and diabetes treatments, with stock up 70% from August low. Analyst Geoff Meacham predicts approval for a weight-loss pill in 2026, expecting $1.8 billion in revenue next year and over $40 billion annually at peak sales, raising price target to $1,500. Jim Cramer also bullish on LLY, citing a deal with Trump administration to lower GLP-1 pricing and expand coverage. Wall Street firms recommend buying LLY shares, given strong pipeline and compelling price-sales ratio of 22x.

Read more at Yahoo Finance: Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?